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Objective: The ideal substitute for the diseased aortic valve is yet to be
found. For the assessment and comparison of the midterm results after
aortic valve replacement with three different types of freehand stentless
xenografts, all patients who underwent the operation between October 1992
and April 1997 were reviewed. Methods: Of 231 patients undergoing aortic
valve replacement, 106 patients (group 1) were given the Biocor PSB
(Biocor Industria e Pesquisa Ltda, Belo Horizonte, MG, Brazil); 76 patients
(group 2) were given the Toronto SPV (St. Jude Medical, Inc., St. Paul,
Minn.), and 49 patients (group 3) were given the O’Brien-Angell valve
(Bravo Cardiovascular model 300, Cryolife, Inc., Marietta, Ga.). The first
two xenografts require inflow and outflow suturelines; the third xenograft
needs a single-sutureline implantation. Mean age (70 6 6 years; 70 6 7
years; 72 6 9 years; p 5 0.6), prevalence of male sex (56 patients, 53%; 37
patients, 49%; 22 patients, 45%; p 5 0.7), of aortic stenosis (72 patients,
68%; 54 patients, 71%; 37 patients, 73%; p 5 0.6), and need for associated
procedures (51 patients, 48%; 30 patients, 40%; 21 patients, 43%; p 5 0.1)
were comparable among groups. Mean aortic crossclamp time was shorter
in group 3 (96 6 24 minutes; 100 6 23 minutes; 88 6 25 minutes; p 5 0.01).
Results: Early deaths were 3 of 106 (3%) in group 1, 2 of 76 (3%) in group
2, and 2 of 49 (4%) in group 3. Follow-up of survivors ranged from 1 to 54
months (mean 32 6 13 months). Survival at 4 years was 90% 6 3% in group
1, 95% 6 3% in group 2, 85% 6 8% in group 3 (p 5 0.3). At 4 years, freedom
from valve-related events was 95% 6 6%, 100%, 70% 6 8% (p 5 0.004),
while freedom from valve deterioration was 99% 6 1%, 100%, 73% 6 8%
(p 5 0.001), in group 1, 2, and 3, respectively (p 5 0.001). At follow-up,
reintervention on the xenograft was necessary in one patient (endocarditis)
in group 1, none in group 2, and six in group 3 (technical cause, group 3;
valve tear, group 2; pannus, group 1). Regression analysis showed O’Brien-
Angell type of xenograft to be predictive of valve-related events (p 5 0.02),
valve deterioration (p 5 0.001), and reoperation (p 5 0.001) during
follow-up. Conclusions: Midterm survival after stentless aortic valve re-
placement is good with all three xenografts. Freedom from valve-related
events, valve deterioration, and reoperation are excellent with the Biocor
PSB or the Toronto SPV stentless valves but less satisfactory with the
O’Brien-Angell valve. (J Thorac Cardiovasc Surg 1998;115:1287-97)
The ideal aortic valve substitute is yet to be found.Despite the low valve-related morbidity associ-
ated with stented porcine xenografts, the evidence
of limited durability and suboptimal hemodynamics,
even with the latest generation of bioprostheses,
continues to represent major shortcomings.1-4
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The observation of more durable results and
favorable hemodynamic performance obtained with
freehand when compared with stent-mounted aortic
homografts5 has prompted a revived interest in a
new generation of stentless porcine xenografts.6
Because of the structural similarity with freehand
homograft valves, stentless prostheses adapt to the
aortic root to reproduce the anatomy of the native
aortic valve. The expectation is that by offering
optimal hemodynamic performance and reducing
the mechanical stress on the valve leaflets, degener-
ation of the bioprosthesis may be slowed and stent-
less xenografts may prove more durable than com-
monly used stented valves.6
Although only the test of time over 10 years after
implantation will prove the value of this hypothesis,
initial experience with stentless aortic xenografts
already allows identification of some of the limita-
tions with the currently available valve models. We
present our clinical experience with aortic valve
replacement (AVR) with three types of freehand
stentless xenografts in 231 patients.
Patients and methods
Patient population. In October 1992, a clinical pro-
gram of AVR with stentless porcine xenografts was
started at the University of Verona. Selection criteria for
enrollment in the study were the same applied to patients
who received stented porcine xenografts, including (1) age
older than 65 years, (2) contraindications to oral warfarin
therapy, and (3) deliberate request of a biologic valve by
the patient. In the latter two cases, a choice among an
aortic homograft, a pulmonary homograft, and a porcine
xenograft was offered to the patient. Children less than 18
years of age were excluded from the study because they
were only offered a pulmonary autograft. When the
decision to replace the aortic valve with a xenograft was
reached, the ultimate choice between stented (Hancock
II, Medtronic, Inc., Minneapolis, Minn.) or freehand
stentless valve was left to the surgeon.
Three different models of stentless porcine bioprosthe-
ses were used for the study, including (1) group 1: the
Biocor PSB valve (Biocor Industria e Pesquisa Ltda, Belo
Horizonte, MG, Brazil); (2) group 2: the Toronto SPV
valve (St. Jude Medical, Inc., St. Paul, Minn.); and (3)
group 3: the O’Brien-Angell valve (Bravo Cardiovascular
model 300, Cryolife, Inc., Marietta, Ga.). The choice of
the type of stentless valve to implant was done by the
surgeon in a nonrandom fashion.
Two hundred thirty-one consecutive patients were in-
cluded in the study between October 1992 and April 1997.
Retrospective review of the patient population showed a
predominantly elderly group of subjects with similar de-
mographic variables among the three groups (Table I).
Primary indication for AVR was aortic stenosis in all
groups, less commonly regurgitation or a combination of
the two. Only five patients had prosthetic valve dysfunc-
tion as indication for stentless AVR (Table I).
Xenograft valve structure and operative technique.
The Biocor PSB valve is a composite valve made of
selected individual porcine cusps, avoiding leaflets with
muscular bands. The leaflets are tanned with glutaralde-
hyde under no pressure and sutured to a conduit of bovine
pericardium. The conduit is then scalloped to mimic the
natural aortic valve.
The Toronto SPV valve is made of a single porcine root
that is fixed under low pressure with glutaraldehyde. The
coronary sinuses are trimmed down to 1.5 to 2.0 mm to
form the base of the leaflets, and the outside wall is
thinned and covered with a Dacron cloth.
The O’Brien-Angell valve is a composite valve made of
three noncoronary leaflets from three different porcine
valves, already fixed with glutaraldehyde under near zero
pressure. The leaflets are sutured together along the free
edges of the aortic wall at the leaflet commissures.
The technique of implantation adopted for the Biocor
PSB and Toronto SPV valve consisted of sizing at the
sinotubular junction and grafting with an inflow (with
interrupted 4-0 multifilament polyester sutures or contin-
uous running 4-0 polypropylene sutures) and an outflow
sutureline with running 4-0 polypropylene sutures.6 Im-
plantation of the O’Brien-Angell valve included sizing at
Table I. Demographic data
Group 1
(Biocor PSB)
Group 2
(Toronto SPV)
Group 3
(O’Brien-Angell) p Value
n 106 76 49
Age (yr) 70 6 6 70 6 7 72 6 8 0.24*
Gender (M/F) 56/50 (53%) 37/39 (49%) 22/27 (45%) 0.67†
Mean NYHA class 2.9 6 0.6 2.9 6 0.7 3.0 6 0.6 0.88*
BSA (m2) 1.75 6 0.18 1.75 6 0.18 1.71 6 0.16 0.39†
AS (no. of patients) 72 54 37 0.74†
AI (no. of patients) 12 8 2 0.46†
AS/AI (no. of patients) 19 13 9 0.70†
Redo AVR 3 1 1 0.89†
BSA, Body surface area; AS, aortic stenosis; AI, aortic insufficiency; AVR, aortic valve replacement.
*One-way ANOVA; †Pearson’s x2.
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the level of the aortic anulus, with selection of a prosthesis
one size larger than measured, and grafting in a supraan-
nular, infracoronary position with running 3-0 polypro-
pylene sutures.7
Shorter aortic crossclamp and cardiopulmonary bypass
times were recorded in group 3 patients as expected
because of the simplified implantation technique of the
O’Brien-Angell xenograft (Table II). The need for asso-
ciated procedures was relatively common in our series and
consisted primarily of myocardial revascularization oper-
ations (Table II). When a concomitant procedure on the
mitral valve was required, an attempt at repair was done
whenever feasible. In case of replacement, a stented
porcine bioprosthesis was always implanted. Replacement
of the ascending aorta in patients with poststenotic dila-
tation ($5 cm diameter) and unilateral or bilateral carotid
thromboendoarterectomy accounted for the remaining
associated procedures. Analysis of the number and type of
associated operations performed did not reveal any dif-
ference among patient groups (Table II).
Follow-up methods. All patients were seen at 1, 6, and
12 months after the operation and on a yearly basis
thereafter. Echocardiographic examination was per-
formed at discharge, at 6 months, and on a yearly basis
thereafter. Follow-up of survivors was last collected be-
tween April 30 and May 15, 1997. Only two (0.9%)
patients could not be reached.
Statistical analysis. Continuous variables were ex-
pressed as means 6 standard deviations, and discrete
variables were expressed as percentage. Comparison
among groups was with the one-way analysis of variance
for continuous variables and Pearson’s x2 test for discrete
ones. Actuarial life table estimates were constructed with
the Kaplan-Meier method and comparison among curves
was carried out with the log-rank test. Multivariable
analysis was performed with the Cox proportional hazards
method8 to identify risk factors for time-related occur-
rence of events after AVR, including (1) any event, (2)
valve-related events, (3) reoperation, and (4) structural
and nonstructural valve deterioration. Definitions of these
events were established according to the recently recom-
mended guidelines.9 The variables entered in the analysis
are listed in the appendix.
Results
Survival. There were seven (3%) early deaths
(,30 days or before hospital discharge). Three (3%)
patients in group 1 died of low output syndrome2
and cerebrovascular accident,1 respectively, 5, 15,
and 45 days after the operation. Two (3%) early
deaths in group 2 were due to low output syndrome
and cerebrovascular accident, 1 and 28 days after
operation. Finally, two (4%) patients in group 3 died
early of cerebrovascular accident and of sepsis, 30
and 50 days after AVR. Follow-up of survivors
ranged from 1 to 54 months (mean 32 6 13 months).
There was a total of nine (4%) late deaths during
the study period. Six (6%) patients in group 1 died
of malignancy (n 5 2), cardiac cause (n 5 2),
pneumonia (n 5 1), and sudden death (n 5 1). Only
one (1%) patient in group 2 died of malignancy.
Two (4%) patients in group 3 died of malignancy
and sudden death. Actuarial 1- and 4-year survival
was comparable in the three groups as shown in
Fig. 1.
Complications. A total of five (2%) patients had
early complications, including two patients in group
3 requiring reoperation. Three patients, one in each
group, had early morbid events including gastroin-
testinal hemorrhage in a patient who was receiving
only oral antiplatelet therapy (group 1), low output
syndrome necessitating intraaortic balloon counter-
pulsation for 3 days (group 2), and postoperative
acute myocardial infarction (group 3). Overall late
(i.e., after discharge or 30 days) complications were
recorded in 15 (7%) patients during follow-up. In six
patients (two in group 1 and four in group 3) morbid
events led to late reoperation, as will be described.
The remaining nine patients who had late compli-
Table II. Operative data
Group 1
(Biocor PSB)
Group 2
(Toronto SPV)
Group 3
(O’Brien-Angell) p Value
n 106 76 49
Crossclamp time (min) 96 6 24 100 6 23 88 6 25 0.01*
Bypass time (min) 129 6 31 133 6 40 119 6 34 0.03*
Valve size (mm): mean, median 24 6 2, 23 25 6 2, 25 24 6 2, 25 0.12*
Associated procedures (no. of patients) 51 30 20 0.15†
CABG (no. of patients) 30 17 15 0.39†
MVR/repair (no. of patients) 11/4 4/4 2/1 0.39†
Ascending aorta replacement (no. of patients) 4 3 1 0.35†
Carotid endoarterectomy (no. of patients) 2 2 1 0.84†
CABG, Coronary artery bypass graft; MVR, mitral valve replacement.
*One-way ANOVA.
†Pearson’s x2.
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cations were seven (7%) patients in group 1 and two
(3%) patients in group 2. In group 1 two patients
had a cerebrovascular complication; three patients
were diagnosed with cancer; one patient had pros-
thetic valve endocarditis; and one patient had com-
plete atrioventricular block that necessitated perma-
nent pacing. Complications in group 2 consisted of
recurrent episodes of pulmonary edema in two
patients with left ventricular failure. Overall event-
free survival was significantly better in groups 1 and
2 than in group 3, with 1- and 4-year estimates of
93% 6 2% and 82% 6 4%, 95% 6 3% and 95% 6
3%, 74% 6 7% and 58% 6 9%, respectively (p 5
0.01).
Valve-related events. When only valve-related
adverse events, including valve-related death, were
considered, a significant difference was noted be-
tween group 1 and 2 patients, who had similar
freedom from events, and group 3, who more com-
monly experienced valve-related complications (Fig.
2). Mulitvariable analysis disclosed O’Brien-Angell
type of xenograft and female gender as incremental
risk factors for a valve-related adverse event during
the study period (Table III).
Only one patient (group 1) in the entire series had
early bleeding complications that could be con-
nected with postoperative oral antiplatelet therapy.
At follow-up, 96% of survivors were free from oral
warfarin therapy.
Two patients in group 1 had cerebral embolism, 1
and 2 years respectively after AVR. None of the
patients had undergone concomitant carotid endo-
arterectomy or had been previously diagnosed with
cerebrovascular pathologic evidence; thus the gene-
sis of the embolic episodes was classified as valve
related.
Only in one patient in group 1 did Streptococcus
bovis prosthetic valve endocarditis develop 3 years
after operation. The patient underwent replacement
of the Biocor xenograft valve with an aortic homograft
and had an uneventful recovery, with no replase of
infection 10 months after homograft root replacement.
Valve deterioration. Structural valve deteriora-
tion was encountered only in two (4%) patients in
group 3 during follow-up. Both women had moder-
ate to severe periprosthetic regurgitation, confirmed
by angiography, respectively 5 and 10 months after
AVR, which led to reoperation.
Nonstructural valve deterioration was recognized
in one (1%) patient in group 1 and in eight (16%)
patients in group 3. The patient with Biocor PSB
AVR was diagnosed with a peak transprosthetic
pressure gradient of 50 mm Hg 6 months after
operation, which remained unchanged at follow-up.
Of the eight patients with O’Brien-Angell xeno-
grafts who had nonstructural valve deterioration,
four underwent reoperation (two early and two late)
because of the severity of prosthetic valve obstruc-
tion and/or worsening symptoms. The remaining
four patients have peak pressure gradients between
52 and 65 mm Hg, which has shown slow progres-
sion at follow-up, and are currently asymptomatic.
Actuarial freedom from valve deterioration for
any cause was significantly lower in patients in group
3 (Fig. 3). Multivariable analysis identified O’Brien-
Angell type of valve and female gender as incremen-
tal risk factors for valve deterioration during fol-
low-up (Table IV).
Fig. 1. Actuarial survival after AVR with three different models of freehand stentless aortic xenografts.
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Reoperation. There were nine reoperations dur-
ing follow-up. Three (3%) patients in group 1
required reintervention, which was unrelated to the
valve in two patients. Third-degree atrioventricular
block developed in one patient 2 years after AVR,
and transvenous pacemaker insertion was required.
A second patient required myocardial revasculariza-
tion 1 year after AVR because of left main coronary
ostium stenosis. At reoperation, inspection of the
Biocor PSB xenograft showed an intact valve and no
anatomic relation with the obstruction of the coro-
nary ostium. The third patient underwent homograft
replacement of the stentless valve because of endo-
carditis, as reported earlier.
Six (12%) reoperations were necessary in group 3,
all because of valve dysfunction. This was identified
as structural in two patients with periprosthetic
regurgitation. At reoperation, a tear of the porcine
aortic wall support of the O’Brien-Angell xenograft
was identified in both patients. In one woman the
xenograft had to be replaced with a stented xeno-
graft; in the other woman, because of the limited
extension of the tear, the stentless xenograft could
be reanchored to the native aortic wall. The remain-
ing four patients underwent reoperation for non-
structural deterioration, which had manifested with
prosthetic valve obstruction (n 5 3) or regurgita-
tion (n 5 1). The cause of the dysfunction was
possibly technical in three cases, resulting in
either inappropriate sizing or incorrect supraanu-
lar positioning of the graft; the dysfunction was
related to early pannus ingrowth in one.10 All
patients survived replacement of the stentless
bioprosthesis with a stented one, which had to be
associated to a Nicks aortic anulus enlargement pro-
cedure in one patient because of extensive scarring of
the aortic root. Actuarial freedom from reoperation
on the prosthesis was significantly lower in group 3
(Fig. 4). Regression analysis demonstrated O’Brien-
Angell type of valve and female gender to be incre-
mental risk factors for reintervention on the xenograft
(Table V).
Functional outcome. Follow-up clinical status
showed significant improvement compared with pre-
operative condition in terms of mean New York
Heart Association functional class in all groups
(2.9 6 0.6 vs 1.4 6 0.7, p 5 0.01, group 1; 2.9 6 0.7
vs 1.1 6 0.4, 0.01, group 2; 3.0 6 0.6 vs 1.4 6 0.8, p 5
0.01, group 3). No difference in terms of clinical
outcome could be identified among the three
groups.
When functional performance of the xenograft
was analyzed by means of transthoracic echocardi-
ography, no instance of prosthetic valve regurgita-
tion greater than mild was detected in any of the
patients, excluding those undergoing reoperation
Fig. 2. Actuarial freedom from valve-related death and morbidity after AVR with three different models
of freehand stentless aortic xenografts.
Table III. Cox regression analysis: valve-related
events
Variable Hazard ratio
95%
Confidence
limits
p
Value
O’Brien-Angell valve 2.46 1.12 5.42 0.03
Female gender 4.26 0.88 20.58 0.07
The hazard ratio associated with the O’Brien-Angell valve describes the
risk of the event associated with the O’Brien-Angell valve versus the risk
associated with both other valves combined; p values are referred to the
coefficients relative to each single covariate.
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for valve deterioration. On the contrary, different
results were found in terms of peak transprosthetic
pressure gradients at 6-month follow-up investiga-
tion among patient groups (Table VI). Although
peak pressure gradients were higher the smaller the
diameter of the valve in each group, as might be
expected, the values were also higher for the same
valve size in patients in group 3 when compared with
patients in both group 1 and group 2. Limited
sampling in the very small and in the very large valve
size categories may account for p values not reach-
ing statistical significance (Table VI).
Discussion
The concept of AVR with a stentless porcine xeno-
graft began with the pioneering work of Binet and
associates11 and O’Brien and associates12 in the mid-
1960s. The recent revival of attention toward stentless
valves moved primarily from the observation of opti-
mal hemodynamic performance and longer durability
of freehand when compared with stent-mounted aortic
homografts.5 Because mechanical stress imposed on
the leaflets of a stented porcine bioprosthesis has been
identified as the major cause of late degeneration,13-15
it was hypothesized that the limitations even with the
latest models of stent-mounted porcine valves1-3 could
be overcome with stentless xenografts.6 Preliminary
reports of ideal hemodynamic function, absolutely
comparable with aortic homografts,16-18 and the ad-
vantage of ready availability in all sizes promoted a
rapid diffusion of a large variety of xenograft models
into the market,6, 18-21 possibly delaying the collection
of significant data to test the durability of these valves.
Unique to the present study is the simultaneous
experience with three types of stentless valves in a
single institution. A retrospective comparison of
clinical and functional results is thus possible.
Replacement of the aortic valve with a stentless
xenograft is a more demanding surgical procedure
and will result in longer periods of myocardial
ischemia when compared with AVR with stented
bioprostheses.16, 17, 20 In addition, freehand aortic
xenografts, which are implanted with inflow and
outflow suture lines, will require longer duration of
ischemia compared with simplified-implant xeno-
grafts, where a single suture line is needed.22 It is
apparent from the data herein that longer aortic
crossclamp time does not adversely affect operative
survival, which was absolutely comparable to age-
matched populations receiving stented bioprosthe-
ses,1-3 as previously shown by others.19-23 This con-
sideration holds true in spite of the high prevalence
of associated disease conditions requiring concomi-
tant surgical management and thus increasing the
operative risk, as evident in our patient population.
It is noteworthy that cerebrovascular accident was as
Fig. 3. Actuarial freedom from structural and nonstructural graft deterioration after AVR with three
different models of freehand stentless aortic xenografts.
Table IV. Cox regression analysis: structural and
nonstructural valve deterioration
Variable Hazard ratio
95%
Confidence
limits
p
Value
O’Brien-Angell valve 7.29 2.36 22.56 0.001
Female gender 9.47 1.20 74.93 0.03
The hazard ratio associated with the O’Brien-Angell valve describes the
risk of the event associated with the O’Brien-Angell valve versus the risk
associated with both other valves combined; p values are referred to the
coefficients relative to each single covariate.
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common a cause of early death as circulatory failure,
possibly because of the advanced mean age of the
patients and the prevalence of vascular disorders.
Midterm survival after stentless xenograft AVR in
the elderly was also satisfactory and in agreement
with previously published series with younger pa-
tients.23 As observed with operative survival, no
difference in terms of midterm survival could be
observed among groups of patients who received the
three different prosthetic devices. Advanced age
could once again account for malignancy being the
leading cause of late death. It would thus be unjus-
tified to reject use of Biocor PSB, Toronto SPV, or
O’Brien-Angell stentless xenografts on the basis of a
presumptive higher risk of operative or late death.
Prevalence of early and late morbidity was overall
low, not exceeding 9% of the entire patient popula-
tion. Complications unrelated to the insertion or
presence of the aortic xenograft were comparable in
the three subgroups and commonly caused by ma-
lignancy or congestive heart failure. When freedom
from all, including valve-related, events was ana-
lyzed, this seemed satisfactory both in patients who
received Biocor PSB and Toronto SPV valves and
comparable with estimates presented after AVR
with stented bioprostheses.1-3 However, a signifi-
cantly poorer outcome was already evident 4 years
after implantation of O’Brien-Angell xenografts.
The demonstration that the difference, in terms of
event-free survival among patient groups, was solely
due to the prevalence of valve-related complications
is evident from Fig. 2. Accordingly, logistic regres-
sion analysis disclosed the latter type of xenograft as
an incremental risk factor for valve-related events
during follow-up. Further assessment showed that
prevalence of hemorrhage, thromboembolism, and
prosthetic valve endocarditis could not account for
the notable difference among the three types of
xenografts. Indeed, these complications were overall
quite uncommon, and no difference among groups
could be disclosed. On the contrary, occurrence of
valve deterioration, rarely or never encountered
respectively after Biocor PSB or Toronto SPV im-
plantation, was prevalent in patients who received
O’Brien-Angell valves. Because the test of time for
a porcine bioprosthesis is durability 8 to 10 years
after implantation,1, 2, 3, 6 an actuarial freedom from
valve deterioration of 73% at 4 years for the latter
xenograft represents a disappointingly low figure
(Fig. 3). Once again, the use of the O’Brien-Angell
prosthesis was isolated as a risk factor for valve
deterioration after stentless AVR. To date this
complication has led 6 of 10 patients in group 3 to
reoperation. Despite a slow tendency to progress,
reintervention in the near future on the remaining
four patients with moderate prosthetic valve ob-
struction cannot be excluded.
Because of the relatively short period of observa-
tion, reoperation on the stentless xenografts was
generally uncommon and never in relation with
calcific degeneration, the well-recognized leading
cause of late failure of stented bioprostheses.24
Aside from a case of replacement of Biocor PSB
xenograft for prosthetic valve endocarditis, reopera-
tion was limited to patients who had received the
O’Brien-Angell bioprosthesis, making implantation
of this device an incremental risk factor for reinter-
vention during the observation period. Structural
failure consisting in a tear of the aortic wall support
of the O’Brien-Angell composite xenograft was ob-
Fig. 4. Actuarial freedom from reoperation after AVR with three different models of freehand stentless
aortic xenografts.
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served in our series.10 Similar complications were
already reported by Hvass and associates22 and
represent elements of concern for a device that is
anchored to the aortic root by means of a single
suture line. Even though replacement of the xeno-
graft may not always be needed, reintervention must
be undertaken whenever a perivalvular regurgita-
tion is observed to verify stability of the prosthesis.
Among causes of nonstructural valve deterioration,
overgrowth of fibrous tissue was also noted early
after AVR with stentless xenografts,10 as previously
described with stented porcine bioprostheses.25 The
most common cause of nonstructural failure of
O’Brien-Angell valves leading to reintervention was,
however, transprosthetic obstruction. By virtue of its
design, this xenograft needs to be implanted in a
subcoronary, but supraannular position, to avoid
protrusion of the porcine aortic wall support into
the left ventricular outflow tract. Despite the appar-
ent simplicity of this concept, technical realization
may not always be as immediate. A variety of
anatomic and pathologic conditions involving the
aortic root will adversely influence the ability to
correctly position the bioprosthesis. Most impor-
tant, a xenograft that is implanted with a single
suture line is more flexible than a two–suture line
stentless valve and will be more easily distorted
when anchored to an asymmetric aortic root. This
may cause obstruction because of the protrusion of
the aortic wall into the aortic orifice, regurgitation
because of the crowding of the leaflets, or both. Our
experience with over 200 implantations of freehand
stentless xenografts suggests that technical mishaps
are not infrequent with the O’Brien-Angell valve,
although these are negligible with either the Biocor
PSB and the Toronto SPV valve. The present find-
ings are at variance with data reported by O’Brien
and associates19 but faithfully reproduce the series
by Hvass and associates,22 who described unsatisfac-
tory postoperative gradients (i.e., nonstructural dys-
function in the present report) in most of their first
50 implantations, thereby confirming the existence
of a steep learning curve.
On the basis of the current experience, reopera-
tion on a failed stentless xenograft does not repre-
sent an exceedingly challenging technical task and
can be performed with excellent survival (no casu-
alties among the seven replacements of the biopros-
thesis).
When the functional properties of stentless aortic
xenografts are evaluated in terms of valve stenosis or
regurgitation, comparison with commonly used
stented bioprostheses appears extremely favorable,
as evident from our clinical series, as well as oth-
ers.6, 16 A wealth of data is already available that
describes the optimal functional results after AVR
with the Toronto SPV valve, including the docu-
mented tendency of the transprosthetic pressure
gradients to decrease over time and the effective
orifice area to increase over time.23, 26 Resolution of
the inflammatory changes of the aortic wall “exclud-
ed” by the xenograft and regression of the left
ventricular hypertrophy have been implicated to
account for these observations. The present experi-
ence with the Toronto SPV valve confirms that the
reported results16, 17, 23, 26 are readily reproducible.
Information on hemodynamic performance of the
Biocor PSB valve is instead limited to one other
institution.21 Comparison with our series is unsound
because of the difference in the age (mean age 36 vs
70 years) and indication to AVR (rheumatic valve
disease in 64% vs senile calcific degeneration in
70%) of the patient population, which possibly
explains the poorer freedom from adverse events in
the experience of others.21 On the basis of our
midterm results on a mostly senescent group of
patients, the Biocor PSB valve proved as depend-
able as the Toronto SPV xenograft both in terms of
freedom from valve-related morbidity and of func-
Table V. Cox regression analysis: reoperation
Variable Hazard ratio
95%
Confidence
limits
p
Value
O’Brien-Angell valve 7.29 2.39 22.83 0.001
Female gender 9.18 1.15 73.30 0.04
The hazard ratio associated with the O’Brien-Angell valve describes the
risk of the event associated with the O’Brien-Angell valve versus the risk
associated with both other valves combined; p values are referred to the
coefficients relative to each single covariate.
Table VI. Six-month follow-up transaortic peak
pressure gradient (mm Hg)
Group 1
(Biocor
PSB)
Group 2
(Toronto
SPV)
Group 3
(O’Brien-
Angell)
p
Value
n 96 73 39
Valve size 21 24 6 15 31 6 16 34 6 10 0.17*
Valve size 23 19 6 11 20 6 9 38 6 27 0.03*
Valve size 25 15 6 8 17 6 8 26 6 20 0.06*
Valve size 27 14 6 4 17 6 7 19 6 8 0.32*
Valve size 29 15 6 8 10 6 5 NA 0.44*
NA, Not applicable.
*Pearson’s x2.
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tional profile. On the contrary, even when cases
labeled as nonstructural deterioration of the pros-
thesis were excluded from observation, peak pres-
sure gradients across the O’Brien-Angell xenograft
tended to be higher in each valve size (Table VI).
Because this graft is implanted with a single suture
line, however, decrease of the degree of obstruction
cannot be expected in the future. Interpretation of
these results does not differ from the explanation of
cases of nonstructural deterioration. When com-
pared with the more lengthy and complicated tech-
nique of grafting of the Biocor PSB and Toronto
SPV valve, implantation of the O’Brien-Angell valve
appears simple. Our work suggests that greater
simplicity may translate into a less predictable early
hemodynamic result.
It must be emphasized that the exact relationship
between postoperative transprosthetic pressure gra-
dients and symptoms is still undefined. In fact, all
patients showed clinical improvement at follow-up
that was not significantly different among the three
groups.
Limitations. There are some notable limitations
to our study. The present work is a retrospective
analysis on a nonrandomized group of consecutive
patients. Thus the issue of comparability of patients
among the three groups becomes crucial. Another
potential limitation may be the decision to select
only elderly patients for this operation. Because of
the predicted life expectancy of individuals in the
seventh or eighth decade of life, the patients at risk
10 years or longer after xenograft valve replacement
could decrease independently from the morbidity of
the prosthesis. The use of statistical analysis to
predict actual rather than actuarial events will then
become necessary.
On the other hand, this experience presents some
unique aspects. It is the only work that compares
three different stentless aortic xenografts at a single
institution. This would allow disclosure of different
learning curves with different devices, if it were the
case. It is a quantitatively sizable series, in that
previously published reports rarely exceed 200 pa-
tients.16-23 Most significantly, it offers insight into
factors that will predict occurrence of adverse events
during a midterm follow-up.
Conclusions
Analysis of over 230 patients undergoing AVR
with three types of freehand stentless xenografts
showed that this more complex surgical procedure
can be performed at a very low operative risk,
comparable among the three groups of patients.
Actuarial survival is also satisfactory as is freedom
from lethal valve-related events. In the present
experience, midterm outcome with the O’Brien-
Angell valve proved less satisfactory in terms of
valve-related morbidity, including structural deteri-
oration of the graft and reoperation. On the con-
trary, prevalence of adverse events after implanta-
tion of either the Biocor PSB and the Toronto SPV
was negligible, and hemodynamic performance is
optimal. Whether the difference in design of the
O’Brien-Angell valve, in and of itself, can justify
these results remains to be proved.
We thank Luisa Zanolla, MD, for the invaluable help in
the statistical analysis of the data.
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Discussion
Dr. Edward D. Verrier (Seattle, Wash.). The surgical
options in the treatment of aortic valve and aortic root
disease have dramatically increased in the last 10 years
with the introduction of a variety of new mechanical
valves, stented porcine and bovine pericardial bioprosthe-
ses, aortic homografts, pulmonary autografts, and now
with the introduction of stentless aortic valves. Biome-
chanical analysis of the composite left ventricular outflow
tract, anulus, leaflets, sinuses, and aortic wall, as well as
complex computer modeling such as finite element anal-
ysis, have suggested that bioprostheses that mimic the
structure, anatomy, and physiology of the normal aortic
root and valve should decrease the stress, strain, and
compliance changes that therefore would equate with a
more durable prosthesis without requiring anticoagula-
tion. The short-term tradeoff for the theoretic long-term
benefit has to do with the technical ease of insertion of the
stentless valves. These valves must be sewn in at the
annular level but must also have the posts constructed
usually with a second suture line.
Dr. Luciani and colleagues at Verona have implanted in
a nonrandomized protocol three different stentless pros-
theses and have followup data of just over 3 years. Their
conclusions are that the Biocor and the Toronto SP valve
are similar and that both are superior to the O’Brien-
Angell valve in terms of valve-related events, valve degen-
eration, and reoperation. Operative death and projected
actuarial survival from nonlethal valve-related events are
similar in all three groups. This is the only study to date
comparing three stentless valves in a single institution.
I have a number of concerns, however, about the study.
First, the study is nonrandomized, and there certainly is a
discrepancy of the size of the three groups. How were the
valves selected for individual patients? Was the series
concomitant or sequential, and if it was sequential, what
order did you trial each valve? How many surgeons were
involved, and did all the surgeons insert all the valves?
Dr. Luciani. The series is not sequential, but rather
concomitant. The reason why we started with three dif-
ferent valves, which is a very curious experience, was that
the Biocor PSB valve was the very first one to be intro-
duced into the market in Europe and Italy, in particular.
When the Toronto SPV and the O’Brien-Angell valves
became available for the Italian market, we decided to test
a valve that was similar to the Biocor PSB and a valve that
was completely different in design. Thus most of the
experience is simultaneous and not sequential. There
were no specific, prospective criteria by which different
models were used by the surgeons; this was left to the
surgeon. Obviously this introduces an element of bias, and
the fact that the study is retrospective also represents an
element of bias.
Your third question was relative to the different sur-
geons; there were three senior surgeons who supervised or
directly performed all the procedures. This factor was
taken into the multivariable analysis, and it did not turn
out to be associated with a different outcome in terms of
functional results or valve deterioration.
Dr. Verrier. Since the follow-up is so short, it is
impossible for me to believe that the conclusions are
anything other than technical considerations rather than
being intrinsically wrong with the O’Brien-Angell valve. In
fact, in the manuscript, you note that the cause of
dysfunction was “possibly technical in at least three cases,
resulting in either inappropriate sizing or incorrect su-
praannular positioning of the graft.” At the recent Sev-
enth International Symposium on Cardiac Bioprosthesis
in Barcelona where your group reported most of these
data, Hvass presented 5 years of follow-up of 366 patients
with the O’Brien-Angell valve. They reported two valve-
related cardiac deaths, both from endocarditis, and only
five reoperations, or less than 1% for nonstructural dys-
function, and none for structural dysfunction. This is in
sharp contrast to the present series in which eight patients
(16%) were reoperated on for nonstructural dysfunction
and two patients (4%) for structural dysfunction. Hvass
reported overall 5-year actual survival of 85% and 95%
for operative survivors. Would you please comment on the
The Journal of Thoracic and
Cardiovascular Surgery
June 1998
1 2 9 6 Luciani et al.
discrepancy between your data and the data from Angell
and his group?
Dr. Luciani. Dr. Hvass published a series of papers
beginning with 1995, one of which, published in the
European Journal of Cardiothoracic Surgery, disclosed a
learning curve with the implantation of the O’Brien-
Angell valve device. Curiously, the same experience was
not reported by Dr. O’Brien, but the person who has the
largest experience with the valve is in fact Dr. Hvass in
Paris, and what he found was that, in the first 50 valves
implanted, the prevalence of “nonstructural” dysfunction
possibly because of technical failure was quite high. The
naming of the phenomenon was quite different; in fact, he
had higher transprosthetic gradients and did not call these
nonstructural valve failures as we did, but possibly the
phenomenon was similar. The second 50 patients he
analyzed had a much lower prevalence of high gradient; in
the last 50 patients in whom he performed the operation
(this was a series of 150 consecutive patients) he actually
could achieve excellent results with minimal prevalence of
this phenomenon. This event may relate to the structure
of the valve that makes it more prone to technical failure.
I do agree with you that our failures are possibly related to
technical cause in many of the nonstructural failure
groups, which apparently occurred at the moment of
implantation and then revealed themselves early on after
follow-up.
Dr. Verrier. My final question relates to echocardio-
graphic follow-up in these patients. Because there are no
stentless valve series in either Europe, Canada, or the
United States that can answer the question of durability,
which will be the key to wider acceptance of this type
valve, most investigators have focused on the small in-
crease in valve area noted over the first 3 months of
implantation and the accelerated decrease in left ventric-
ular wall mass over the first 6 months. This is a particular
advantage noted by most investigators with the stentless
prosthesis over the stented bioprosthesis. Can you give
any data supporting the superiority of any of these three
valves in terms of these very definable, objective end-
points?
Dr. Luciani. We do not have any data to support the
increase in effective orifice size 3 months after implanta-
tion. We have only been following the flow across the
valve in terms of peak and mean transprosthetic gradients
and the degree of mass regression.
Dr. Thomas A. Pfeffer (Los Angeles, Calif.). During the
past 4 years, our group in Los Angeles has implanted 93
Freestyle valves manufactured by Medtronic which, as far
as I am aware, is the only stentless valve with imminent
release for general use in the United States. At 4 years,
approximately 78% of our patients have no aortic insuf-
ficiency and about 22% have grade 1 or more aortic
insufficiency, none of whom have undergone reoperation.
This is essentially unchanged from our initial postopera-
tive echocardiographic findings. My question relates
somewhat to the discussion of the Ross procedure earlier
this morning that had to do with the importance of valve
sizing for this procedure. Didn’t you comment on the
technique of implantation, whether all of them were
subcoronary or modified subcoronary or done as root
replacements, and whether this would have any impact on
the results with these valves?
Dr. Luciani. I am sorry that, because of time con-
straints, I could not go into the details of technique of
implantations. The three valves that we used cannot be
implanted in the different manners that you explained;
they can only be implanted as subcoronary, freehand
grafts, because they do not retain the native roots; you
cannot scallop them and, alternatively, implant them as
miniroot, total root, or complete freehand. Both the
Biocor PSB and Toronto SPV valve need to be implanted
as freehand with inflow and outflow sutures much like
freehand homografts.
The O’Brien-Angell valve has a different technique of
implantation, which is single suture line; in fact, it is three
distinct running suture lines that anchor the valve not at
annular level but at supraannular level. We believe that
this specific feature of the valve, which is at one time very
attractive, at the same time may be somewhat less readily
apparent for the surgeon and less ready to be learned by
the surgeon in terms of implantation technique.
Dr. Philip W. Wright (Honolulu, Hawaii). Are there
disqualifying characteristics of systolic left ventricular
function preoperatively in the selection of patients that
influence the outcome or, in your practice, would influ-
ence the type of patients that you operate on?
Dr. Luciani. This is a series of nonselected patients in
the way they were not prospectively randomized, so that
left ventricular function was taken into consideration, and
the low number of cardiac deaths compared with series
that used stented procedures may explain the difference of
death connected with device implantation.
Appendix
Varibles entered in the multivariable analysis with the
Cox proportional hazards method as covariates included:
age, gender, indication to operation, endocarditis as a
cause of aortic insufficiency, presence of a bicuspid aortic
valve, associated coronary artery disease, name of sur-
geon, need for associated procedures, size of xenograft
valve, type of prosthetic device, duration of aortic cross-
clamp time, use of blood cardioplegia, and immediate
postoperative transaortic peak pressure gradient.
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